The company said that more than 800 people have been treated with Elevidys, with only one experiencing liver failure.

making it one of the most expensive therapies in the U.S. Mizuho said the selling of the stock was likely an overreaction, noting that this is the first case of acute liver failure among patients ...

Wondering where Apple stock may be in five years? Learn what the current state of AAPL stock is and what its five year ...

Samsung Electronics is set for a tough annual general meeting on Wednesday with shareholders frustrated by its failure to ...

Sarepta Therapeutics shares dropped 20% after a patient's death raises Elevidys safety concerns. Read why I am downgrading ...

Sarepta shares fell after reporting a patient death linked to Elevidys. The case involved acute liver failure, with a CMV infection as a potential factor.

Sarepta Therapeutics Inc.'s stock was down 21.6% in premarket trades on Tuesday after the commercial-stage biopharmaceutical company said a patient died from liver failure after using its drug ...

BBBY investors believed Donald Trump’s nominee to lead the Federal Housing Finance Agency, had insights into the stock’s ...

Sarepta Therapeutics said a patient taking its treatment for Duchenne muscular dystrophy has died from acute liver failure.

The South Korean firm has been suffering from weak earnings and sagging share prices in recent quarters after falling behind ...

There was a pretty tight contest between activists and incumbents for board seats at Matthews International. Check out our ...